academic article

• Impact of Anticholinergic Burden and Clinical-Demographic Characteristics on Incident Dementia in Parkinson Disease..  Journal of geriatric psychiatry and neurology.  -. 2025
• "Reply: Improving Insight and Application: A Commentary on the Link between Initial Depression and Anxiety and Long-Term Health Outcomes in Parkinson's Disease Patients"..  Movement disorders clinical practice.  11:1648-1649. 2024
• Long-Term Dementia Risk in Parkinson Disease..  Neurology.  103:-. 2024
• Improving Parkinson's Disease Care through Systematic Screening for Depression..  Movement disorders clinical practice.  11:1212-1222. 2024
• Association of Baseline Depression and Anxiety with Longitudinal Health Outcomes in Parkinson's Disease..  Movement disorders clinical practice.  11:1103-1112. 2024
• Genetic and phenotypic characterization of Parkinson's disease at the clinic-wide level..  NPJ Parkinson's disease.  10:-. 2024
• Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease..  Parkinsonism & Related Disorders.  -. 2023
• Potentially inappropriate medications in older adults with Parkinson disease before and after hospitalization for injury..  Parkinsonism & Related Disorders.  -. 2023
• Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies..  Neurotherapeutics.  20:375-388. 2023
• Hallucinations, Antipsychotic Use, and Mortality in Older Adults with Dementia: Retrospective Cohort Study of Two Medicare-Linked National Health Surveys..  Drugs & aging.  39:967-974. 2022
• Atypical antipsychotic use and mortality risk in Parkinson disease..  Parkinsonism & related disorders.  17-22. 2022
• Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers..  Parkinsonism & related disorders.  33-36. 2022
• Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?.  Movement disorders clinical practice.  8:1181-1188. 2021
• Medicare Claims Data Underestimate Hallucinations in Older Adults With Dementia..  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.  30:352-359. 2021
• Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?.  BMC neurology.  21:-. 2021
• Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias..  Neurology.  96:e1855-e1864. 2021
• Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease..  Journal of Parkinson's disease.  11:737-745. 2021
• Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study..  Journal of Parkinson's disease.  11:757-765. 2021
• Tau pathology associates with in vivo cortical thinning in Lewy body disorders..  Annals of clinical and translational neurology.  7:2342-2355. 2020
• Frequency of and risk factors for potentially inappropriate medication use in Parkinson's disease..  Age and ageing.  49:786-792. 2020
• Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?.  Movement disorders : official journal of the Movement Disorder Society.  35:1618-1625. 2020
• Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease..  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.  29:35-47. 2020
• Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies..  Parkinsonism & related disorders.  119-124. 2019
• Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants..  Movement disorders clinical practice.  6:440-445. 2019
• Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease..  JAMA Neurology.  76:41-49. 2019
• Pharmacological treatment of apathy in Lewy body disorders: A systematic review..  Parkinsonism & related disorders.  14-24. 2018
• APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  33:289-297. 2017
• Longitudinal decline in speech production in Parkinson's disease spectrum disorders..  Brain and language.  42-51. 2017
• Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1..  Journal of Parkinson's Disease.  7:117-127. 2017
• Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis..  Journal of Parkinson's disease.  7:385-395. 2017
• Statins and Cognition in Parkinson's Disease..  Journal of Parkinson's disease.  7:661-667. 2017
• Hospital care for mental health and substance abuse conditions in Parkinson's disease..  Movement Disorders.  31:1810-1819. 2016
• Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease..  Journal of neurology, neurosurgery, and psychiatry.  87:1303-1310. 2016
• Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx)..  Journal of Parkinson's disease.  6:383-92. 2016
• The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease..  Parkinsonism & related disorders.  21-6. 2016
• Longitudinal study of normal cognition in Parkinson disease..  Neurology.  85:1276-82. 2015
• Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire..  Movement disorders : official journal of the Movement Disorder Society.  31:126-34. 2015
• Caregiver report of apathy predicts dementia in Parkinson's disease..  Parkinsonism & related disorders.  21:992-5. 2015
• Genetic influences on cognitive decline in Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  27:512-8. 2012